Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KR-pep-2D
- Development stage
- Preclinical
- Lead developer
- University of Tokyo
- Modality
- Peptides
01
Overview
KR-pep-2D is a macrocyclic peptide inhibitor that targets the KRAS protein, specifically exhibiting high affinity for the KRAS G12D mutant. Discovered using the RaPID (Random non-standard Peptide Integrated Discovery) system, it binds to the switch II pocket of KRAS in its active, GTP-bound state. This binding sterically hinders the interaction between KRAS and its downstream effectors, such as RAF kinases, thereby suppressing oncogenic MAPK/ERK signaling. KR-pep-2D is primarily utilized as a research tool and tool compound in preclinical studies, including therapeutic screening assays with patient-derived pancreatic cancer organoids, to evaluate the sensitivity of KRAS-mutant models to targeted inhibition.
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)
Beyond the preview
Go deeper on KR-pep-2D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KR-pep-2D.